Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

SOHO 2020 | Impact of COVID-19 on the management of MDS

Rami Komrokji • 27 Aug 2020
SOHO 2020
Myelodysplastic Syndromes

Rami Komrokji, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, discusses the impact of the COVID-19 pandemic on the treatment and management of patients with myelodysplastic syndrome (MDS). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Rami Komrokji

Evolving strategies in clinical trial design for MDS: defining response criteria
15:13
Evolving strategies in clinical trial design for MDS: defining response criteria
Rami Komrokji • 28 Jun 2025
Updates on the diagnosis, risk stratification and treatment of lower-risk MDS
Updates on the diagnosis, risk stratification and treatment of lower-risk MDS
Rami Komrokji • 27 Oct 2023
Personalizing the timing of SCT in patients with myelofibrosis
2:13
Personalizing the timing of SCT in patients with myelofibrosis
Rami Komrokji • 24 Aug 2024
Should we move beyond JAK inhibitors in MPNs?
0:59
Should we move beyond JAK inhibitors in MPNs?
Rami Komrokji • 24 Aug 2024

Related Videos

The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
2:53
The ACCESS study: impact of HLA disparity on transplant outcomes in patients receiving MMUD grafts
Rami Komrokji • 6 Dec 2025
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
1:07
Practice-changing highlights in MDS from ASH 2025: the VERONA trial and triplet combinations
Rami Komrokji • 6 Dec 2025
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
5:58
Outcomes of HMA plus venetoclax in HR-MDS: an analysis from the icMDS validate database
Rami Komrokji • 16 Dec 2025
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
1:30
Olutasidenib with co-targeted therapy in R/R IDH1-mutated myeloid malignancies: Phase II trial
Rami Komrokji • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals